Home | FCA & regulatory news | British English edition
Trade Hub UK

Independent coverage of UK markets, FCA policy and institutional trading
AD CME Group Education AD Bank of England Statistics AD Investing.com Markets AD LSEG Data
Venues & MTFs

Kairos Pharma Reports Interim PFS Benefit For ENV-105 In Phase 2 Prostate Cancer Trial

Trade Hub UK regulation desk (2026-10-06): Kairos Pharma Reports Interim PFS Benefit For ENV-105 In Phase 2 Prostate Cancer Trial (RTTNews) - Kairos Pharma, Ltd. (KAPA), a clinical-stage… Primary source: original at Nasdaq Market Structure (nasdaq.com).

By Nasdaq Market Structure

Kairos Pharma Reports Interim PFS Benefit For ENV-105 In Phase 2 Prostate Cancer Trial

(RTTNews) - Kairos Pharma, Ltd. (KAPA), a clinical-stage biopharmaceutical company, announced positive interim efficacy data from its ongoing Phase 2 clinical trial evaluating ENV-105 in combination with apalutamide in patients with metastatic castration-resistant prostate cancer

Read at source

Read also
  1. Tesla Just Delivered Excellent News, but Is the Stock a Buy?
  2. Brazilian Real Strength Supports Coffee Prices
  3. Warren Buffett's Overlooked AI Race Pick
  4. Japan Stock Market May See Additional Support
  5. Nebius Has Been One of 2026's Best-Performing AI Cloud Stocks. Here's What $1,000 Invested Could Be Worth by 2030.

Source: Nasdaq Market Structure